Liquidia (LQDA) Stock: Buy, Sell, or Hold?
LQDA - Liquidia Corporation Common Stock
$66.74
-1.11 (-1.64%)
▼
5d:
-2.75%
30d:
-15.29%
90d:
-6.82%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Sep 9, 2026 at $68.48 · last confirmed Sep 9, 2026
Strength: 5.2/10
Get Alerted When LQDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LQDA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: LQDA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$132.03
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$81.98
18.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LQDA is currently trading at $66.74, which is considered oversold relative to its 30-day fair value range of $67.83 to $84.47. The stock's valuation (Forward PE: 11.8) is in line with its historical norms (12.0). Remarkably, the market is currently pricing in an annual earnings decline of 0.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, LQDA is in a strong uptrend. The price is currently testing key support at $66.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LQDA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $107.75 (+61.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LQDA is in a strong uptrend. The price is currently testing key support at $66.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LQDA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $107.75 (+61.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$67.83 -
$84.47
Company Quality Score
70/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (88/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.4% below Wall St target ($107.75)
- BULLISH: Bottoming setup score 88/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$67.83 -
$84.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$66.10
Resistance Level
$70.75
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.81
Wall Street Target
$107.75
(+61.4%)
Revenue Growth (YoY)
1842.7%
Profit Margin
30.7%
Valuation Discount vs History
-0.6% cheaper
PE vs Historical
11.8 vs 12.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.6%
(market-implied from PE analysis)
1-Year Target
$66.34
(-1%)
2-Year Target
$65.94
(-1%)
3-Year Target
$65.55
(-2%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
$66.59
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 75.5%)
$384.62
(+476%)
Base:
(SPY PE: 11.8, Growth: 75.5%)
$225.25
(+238%)
Bear:
(PE: 10.0, Growth: 75.5%)
$191.46
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (49x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 49.17 | Current EPS (TTM): $1.38
Bull Case
$149.27
(+124%)
Analyst growth 100.0%, PE expands to 54.1
Base Case
$135.70
(+103%)
Market implied 100.0%, PE stable at 49.2
Bear Case
$46.14
(-31%)
Severe decline -20.0%, PE contracts to 41.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.8 to 12.0
Stabilization Target:
$67.80
(+1.6%)
PE Expansion Potential:
+1.6%
Share & Embed Analysis
Last updated: September 11, 2026 7:52 PM ET
Data refreshes hourly during market hours. Next update: 8:52 PM
Data refreshes hourly during market hours. Next update: 8:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LQDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger Jeffs
SELL
18839 shares
2026-04-17
Michael Kaseta
SELL
139390 shares
2026-04-15
Roger Jeffs
SELL
25000 shares
2026-04-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
Advanced LQDA Option Strategies
Professional options setups generated by AI based on today's LQDA price and gamma walls.